wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37633408-0FDE8C52-21C5-4305-9466-07A5207E884C
Q37633408-0FDE8C52-21C5-4305-9466-07A5207E884C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37633408-0FDE8C52-21C5-4305-9466-07A5207E884C
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
P2860
Q37633408-0FDE8C52-21C5-4305-9466-07A5207E884C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37633408-0FDE8C52-21C5-4305-9466-07A5207E884C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2088ec600eee437545dd4aef4a0d786cba1c61f1
P2860
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.